Non-invasive tests for resmetirom treatment fail to accurately define the target population: Evidence from a biopsy-proven masld cohort

Hepatology Forum · Published 2025-01-01 · DOI 10.14744/hf.2025.2025.0050

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.14744/hf.2025.2025.0050

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Discriminative performance of non-invasive scoring systems for VCTE defined steatosis and fibrosis in patients with psoriasis · Hepatology Forum · 2026 · Same journal
• Methylprednisolone for Swietenia macrophylla seeds-induced liver injury: A case report · Hepatology Forum · 2026 · Same journal
• A traditional herbal remedy in liver diseases: Momordica charantia L. (kudret narı/bitter melon) · Hepatology Forum · 2026 · Same journal
• Occult B hepatitis infection · Hepatology Forum · 2026 · Same journal
• Prevalence of metabolic dysfunction-associated steatotic liver disease among obese, overweight, and at-risk children and adolescents in Türkiye: A meta-analysis · Hepatology Forum · 2026 · Same journal
• Microplastics and nanoplastics: Emerging drivers of hepatic pathogenesis and metabolic dysfunction · Hepatology Forum · 2025 · Same journal
• Association of dermatomyositis and autoimmune hepatitis: A case report · Hepatology Forum · 2025 · Same journal
• Chanarin-Dorfman Syndrome: Two siblings with steatohepatitis, cirrhosis, and a novel mutation · Hepatology Forum · 2026 · Same journal
• Acetaminophen toxicity: Patterns of liver injury and effect on hospital length of stay, and need for inpatient psychiatric care · Hepatology Forum · 2026 · Same journal
• From dysbiosis to MASLD: The central role of the gut microbiota · Hepatology Forum · 2026 · Same journal